Search by category
01.15.2020 | genomeweb | CTC and Liquid Biopsy
Circulating Tumor Cell Collection, Analysis Methods Make Headway in 2019NEW YORK – 2019 was a busy year for circulating tumor cell (CTC) capture and detection, as academic and commercial groups continued to develop novel techniques to extract and purify CTCs for diagnosing several cancers, and accelerated their efforts to bring these technologies to the clinic. Notably, companies are increasingly exploring CTC capture methods alongside circulating tumor DNA (ctDNA) purification and analysis tools to distinguish themselves from the crowded ctDNA detection space and potentially unlock additional liquid biopsy applications.
12.27.2019 | Fierce Biotech | CTC and Liquid Biopsy
Blood Testing Nears a Turning Point as the Evidence Becomes UndeniableBlood has always held the keys to our bodies’ health: it helps carry nutrients in and waste out, and interrogating it can provide solace when we are well and answers when we are sick. Blood testing is ubiquitous, but it’s clear its possibilities are unfulfilled. Through different methods and modalities, these diagnostics promise to be a more accessible, less invasive, smarter, cheaper and a comprehensive way to gather knowledge about what’s going on under the skin—whether in a doctor’s office, at home or within a clinical laboratory.
12.19.2019 | American Journal of Managed Care: AJMC | CTC and Liquid Biopsy
Personalizing Breast Cancer: How Liquid Biopsy Testing for ctDNA, CTCs Can Promote Preventive CareTwo abstracts on liquid biopsy tests revealed the potential of analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in promoting heightened decision-making by clinicians for patients with early-stage and metastatic breast cancer.
07.01.2019 | Genetic Engineering & Biotechnology News | CTC and Liquid Biopsy
Liquid Biopsy Technologies Diversify in Expanding CTC FieldThe field of circulating tumor cells (CTCs) is exploding with competing technologies, all offering different approaches to isolating and characterizing CTCs from blood. CTCs are incredibly rare. Out of ten billion blood cells, only a handful may be CTCs. They are believed to be the mechanism behind cancer metastasis, and there is a great deal of interest in using them to diagnose, monitor, and predict the course of the disease.
04.05.2019 | COMPELO | AR-V7 and Prostate Cancer
Epic Sciences unveils new liquid biopsy test to predict sensitivity to PARP inhibitors in prostate cancer trialEpic Sciences and its research partners report the use of the company’s new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of drug resistance in patients with metastatic castration-resistant prostate cancer (mCRPC). The assay is being utilized as a selection device in BeiGene, Ltd.’s ongoing Phase 2 clinical trial with its investigational PARP inhibitor (pamiparib) in this patient population (NCT03712930).
03.27.2019 | The Pathologist | CTC and Liquid Biopsy
A Fluid Future - Why are there inconsistencies between different liquid biopsy tests – and how can the field evolve to maximize accuracy and impact?Advances in disease profiling over recent years have opened new doors in the quest for early diagnosis and personalized treatment, with metastatic prostate cancer being a case in point. As the most widespread malignancy affecting men in the USA – 174,650 new cases and 31,620 deaths are predicted for 2019 – prostate cancer research is crucial. One such breakthrough is the use of liquid biopsy tests to detect circulating tumor DNA (ctDNA) in patients’ blood, offering a minimally invasive method of disease profiling.
03.25.2019 | FierceBiotech | About Us
Epic Sciences nets Myriad’s cancer president to serve as its CEOLiquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO. Sanders takes over for Murali Prahalad—who is stepping down after six years to pursue new opportunities, according to the company—though Prahalad will maintain a seat on Epic’s board of directors.
03.20.2019 | 360Dx | AR-V7 and Prostate Cancer
Epic Sciences Nabs NY State Approval for AR-V7 Prostate Cancer TestNEW YORK (360Dx) – Epic Sciences said today that its lab is now licensed by the New York State Department of Health to provide its Oncotype DX AR-V7 Nucleus Detect test for residents with metastatic castration-resistant prostate cancer.
03.19.2019 | medwireNews | AR-V7 and Prostate Cancer
AR-V7 status predicts abiraterone, enzalutamide response in mCRPCThe PROPHECY study represents a multicenter effort that provides prospective, blinded clinical validation around such an approach and suggests that both the JHU CTC AR-V7 mRNA assay and the Epic CTC nuclear-specific AR-V7 protein assay provide clinical utility around the anticipated outcomes with therapy.
03.18.2019 | MEDPAGETODAY | AR-V7 and Prostate Cancer
Test Predicts Resistance to Hormonal Therapy in Prostate Cancer - Validation study confirms assist in decision-makingA blood test that measures the spliced variant of an androgen receptor called AR-V7 in circulating tumor cells successfully predicted resistance to commonly used hormonal therapy agents in advanced prostate cancer, a validation study confirmed.
03.14.2019 | BioSpace | AR-V7 and Prostate Cancer
Large Prospective Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences' Platform to Predict Treatment Outcomes for Patients with Advanced Prostate CancerEpic Sciences, Inc. (Epic) today announced the publication of results from a multicenter prospective trial validating the biomarker AR-V7 (androgen receptor splice variant-7) as a predictor of resistance to anti-androgen therapy in men with metastatic castration-resistant prostate cancer (mCRPC). Data from the PROPHECY trial, published in the Journal of Clinical Oncology, demonstrate that detection of AR-V7 in circulating tumor cells (CTCs) in blood is predictive of whether men with mCRPC have become resistant to androgen-receptor signaling (ARS) inhibitors and have a low chance of benefit from further ARS therapy.
03.14.2019 | OncLive | AR-V7 and Prostate Cancer
CTC AR-V7 Validated as Predictive Marker of Resistance to AR-Directed Therapy in mCRPCNuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells (CTCs) is a predictive marker of shorter progression-free and overall survival (OS) with antiandrogen therapy in patients with metastatic castration-resistant prostate cancer (mCRPC), according to results from the phase III PROPHECY trial that were published in the Journal of Clinical Oncology.
03.13.2019 | Duke Cancer Institute | AR-V7 and Prostate Cancer
Blood Tests Predict Effectiveness of Hormonal TherapiesA multi-institutional group of clinical researchers, led by the Duke Cancer Institute’s Andrew Armstrong, MD, McS, FACP, published a new report this month in the Journal of Clinical Oncology, that describes results from the PROPHECY study, which prospectively compared two blood tests to assess how well they predicted the effectiveness of hormonal therapy in men with metastatic prostate cancer.
03.13.2019 | Xconomy | AR-V7 and Prostate Cancer
Blood Test Study Meets Goal, Validates Epic’s Prostate Cancer TargetEpic Sciences has commercialized a blood test that can predict how likely a patient with late-stage prostate cancer treated with hormones is likely to respond to an additional course of such therapy. Now, the San Diego-based company has additional data that it says supports use of its tests to determine when not to use hormone therapy.
02.17.2019 | UroToday | AR-V7 and Prostate Cancer
ASCO GU 2019: A Phase II Trial in Progress: Pamiparib, an Investigational PARP Inhibitor, in Patients with mCRPC and a Circulating Tumor Cell Homologous Recombination Deficiency Phenotype or BRCA DefectsSan Francisco, CA (UroToday.com) Prostate cancer is one of the leading causes of cancer deaths in men. Patients with metastatic castration-resistant prostate cancer (mCRPC) who have a BRCA1/2 mutation or mutations in other homologous recombination deficiency genes have aggressive disease and a worse prognosis. Poly (ADP-ribose) polymerase (PARP) proteins are a family of proteins involved in DNA repair, genome stability, and programmed cell death. Inhibition of PARP proteins allows for the accumulation of unrepaired single-strand breaks, which are converted to double-strand breaks during cell division and can lead to apoptosis/cell death. DNA repair can be compromised by the absence of homologous recombination components such as BRCA1 or BRCA2.
01.08.2019 | genomeweb | CTC and Liquid Biopsy
Circulating Tumor Cell Capture Technologies Expand in 2018NEW YORK (GenomeWeb) – The market for circulating tumor cell (CTC) capture and detection grew significantly in 2018 as several companies pushed toward clinical implementation of their technologies for diagnosing multiple cancers, while new firms spun out of academic institutions with their own technologies. In order to diagnose cancer clinicians have traditionally performed tissue biopsies, which can be invasive, expensive, and time-consuming for patients. Over the last decade, however, liquid biopsy tools have emerged as a way to address these issues and perhaps provide a more accurate picture of individual patients’ disease.
01.08.2019 | Medium | CTC and Liquid Biopsy
The Race to Diagnose Cancer With a Simple Blood TestFive years ago, a team of researchers pored over the results of a prenatal genetic test given to more than 125,000 healthy pregnant women and made a stunning discovery. The blood test, marketed by gene-sequencing giant Illumina, was designed to detect chromosome anomalies associated with conditions such as Down syndrome by analyzing fragments of fetal DNA circulating in the mother’s blood. In 3,757 of the tests, the scientists found at least one abnormality. But in 10 of those cases, further analysis revealed that the fetuses were in fact normal. “In every one of those 10 cases, it turned out there was an undiagnosed cancer” in the mother, says Alex Aravanis, who at the time of the study was the senior director of research and development at Illumina.
12.07.2018 | KATU2 | AR-V7 and Prostate Cancer
Video - Genomic Sequencing: Precision data to better fight advanced cancerPortland, KATU2 — Patient Bryce Olson shows the importance of personalized medicine, including the Oncotype DX® AR-V7 Nucleus Detect™ test, in aiding pivotal metastatic castration-resistant prostate cancer treatment decisions. The test, developed by Epic Sciences and commercially available by Genomic Health, is now covered by Medicare.
12.02.2018 | UroToday | AR-V7 and Prostate Cancer
Video - PROPHECY Trial: Circulating Tumor Cell as a Biomarker in mCRPC - Andrew ArmstrongSan Diego, UroToday — Charles Ryan and Andrew Armstrong discuss the PROPHECY study, a PCF challenge award, co-funded by Movember. Seeing the future with predictive biomarkers was the foundational vision for this study. For men with castration-resistant prostate cancer undergoing a range of therapies, two AR-V7 tests were prospectively compared to see how well they predicted both progression-free survival and overall survival.
11.12.2018 | ABC 10 | AR-V7 and Prostate Cancer
Video - New test extending lives of advanced prostate cancer patientsBryce Olson discusses the Oncotype DX® AR-V7 Nucleus Detect™ test, developed by Epic Sciences and commercially available through Genomic Health, with ABC 10 News. The test determines which men with late-stage metastatic prostate cancer will benefit from AR-targeted therapy or chemotherapy.
11.06.2018 | CLP Magazine | AR-V7 and Prostate Cancer
Blood Test May Identify Cancer Patients Who Respond to PSMA-Targeted TherapiesSan Diego, CLP Magazine — In a study sponsored by Epic Sciences, San Diego, in partnership with Memorial Sloan Kettering Cancer Center, researchers have demonstrated that a liquid biopsy blood test may be used before treatment is initiated in clinical trials to find patients who are likely to benefit from therapies targeting prostate-specific membrane antigen.
11.05.2018 | GenomeWeb | Functional Cell Profiling
Metastatic Breast Cancer Clinical Trial Forged by Epic Sciences, Canadian ConsortiumNew York, GenomeWeb – Epic Sciences announced today that it has partnered with four major Canadian breast cancer centers on a clinical trial to see if the firm’s blood test can be used to predict the risk of late recurrence of metastatic breast cancer in female patients.
10.29.2018 | Clinical OMICs | AR-V7 and Prostate Cancer
Epic Sciences, Genomic Health Get Medicare LCD for Prostate Cancer DiagnosticSan Diego, Clinical OMICs – Epic Sciences and Genomic Health announced that Medicare Administrative Contractor Palmetto GBA, has issued a positive final local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test. The final LCD recommends Medicare coverage effective December 10, 2018.
10.03.2018 | GenomeWeb | AR-V7 and Prostate Cancer
Epic Sciences Continues Research on Multiple Fronts; Remains Quiet on Dx Development PipelineNew York, GenomeWeb – With its first commercial diagnostic now fully launched and awaiting a final coverage decision by Medicare, Epic Sciences is keeping quiet about concrete plans for a pipeline of additional clinical assays, though it continues to collect data from research studies which may provide possibilities for future translation.
09.26.2018 | San Diego Business Journal | Functional Cell Profiling
Epic Aims to ‘Revolutionize Cancer Care'San Diego, SDBJ — Epic Sciences’ pitch: greater certainty. The company’s portfolio of tests guide cancer doctors deciding on a treatment path, including a test on the market for advanced prostate cancer.
09.24.2018 | Clinical OMICs | AR-V7 and Prostate Cancer
Study Shows Epic Sciences Liquid Biopsy Aids Prostate Cancer Patient SelectionSan Diego, Clinical OMICs – Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment.
09.12.2018 | Medical Device and Diagnostics Industry | Functional Cell Profiling
An Epic Approach To Liquid BiopsySan Diego, MDDI – The liquid biopsy space continues to attract investors and bring in financings that are typically above the average amount medtech firms are able to raise. Epic Sciences is the latest liquid biopsy company to obtain funding and has raised about $52 million in a series E round.
07.17.2018 | OncLive | AR-V7 and Prostate Cancer
CTC AR-V7 Assay Shows Promise as Treatment Guide in mCRPCSan Diego, OncLive — An assay for nuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells (CTCs) identified patients with metastatic castration-resistant prostate cancer (mCRPC) who had better outcomes from treatment with taxanes, and those who did better with androgen receptor-signaling (ARS) inhibitors.
07.02.2018 | Xconomy | AR-V7 and Prostate Cancer
Study: Blood Test for Prostate Cancer Can Guide Therapy, Extend LivesSan Diego, Xconomy — Blood tests for cancer, known as liquid biopsies, have become available in recent years to guide treatments for people already diagnosed. But how useful are they? A paper published last week in the journal JAMA Oncology makes the case that one such test, Oncotype DX AR-V7 Nucleus Detect, might be worth its $3,980 price tag.
07.02.2018 | European Pharmaceutical Review | AR-V7 and Prostate Cancer
Blood test predicts treatment response for metastatic prostate cancerSan Diego, European Pharmaceutical Review — Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy…
06.28.2018 | GenomeWeb | AR-V7 and Prostate Cancer
Study Validates Oncotype DX AR-V7 Chemo PredictionNew York, GenomeWeb – A newly published multi-institutional cohort study has validated Epic Sciences’ circulating tumor cell-based AR-V7 test, now marketed by Genomic Health as Oncotype DX AR-V7 Nucleus Detect. The blinded study, published in JAMA Oncology, enrolled 142 patients with metastatic castration-resistant prostate cancer who were treated with either taxanes or androgen receptor signaling (ARS) inhibitors and observed for up to 4.3 years.
06.06.2018 | Cancer Network | AR-V7 and Prostate Cancer
AR-V7+ CTCs Predicted Worse PFS, OS in mCRPCSan Diego, Cancer Network — Detection of circulating tumor cells (CTCs) positive for the nuclear-specific AR-V7 protein was an independent predictor of shortened progression-free survival (PFS) and overall survival (OS) when treating metastatic castration-resistant prostate cancer (mCRPC) with abiraterone or enzalutamide, according to results of the PROPHECY study (abstract 5004). The findings were presented at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO), held June 1–5 in Chicago.
06.05.2018 | MedicalXpress | AR-V7 and Prostate Cancer
Tests identify who would benefit from advanced prostate cancer therapiesSan Diego, MedicalXpress – Two blood tests can predict which subset of men with advanced prostate cancer will likely not benefit from anti-androgen therapies, providing doctors and patient added clarity on treatment options, according to a study led by Duke Cancer Institute. The blood tests, dubbed “liquid biopsies”, detect androgen receptor splice variant-7 (AR-V7) circulating in prostate tumor cells. The presence of this variant indicates a poor response to new androgen receptor drugs that are used to treat recurrent, metastatic prostate cancer.
04.28.2018 | MedCity News | Functional Cell Profiling
Biopharma just can’t get enough of Epic SciencesSan Diego, MedCity News — Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.
12.06.2017 | San Diego Union-Tribune | Functional Cell Profiling
An Epic Quest to Detect CancerSan Diego, San Diego Union-Tribune – Finding needles in a haystack is the life-and-death job of San Diego’s Epic Sciences. The needles are extremely rare cancer cells that hide among the millions of normal cells in the blood of cancer patients.
08.14.2017 | OncLive | AR-V7 and Prostate Cancer
Video - Prostate Cancer: Epic Sciences AR-V7 TestSan Diego, OncLive — Insights From: Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine; Andrew J. Armstrong, MD, MSc, Duke Cancer Center; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center
04.13.2017 | GenomeWeb | CTC and Liquid Biopsy
Liquid Biopsy Market Sees Continuing Growth of New Technologies, MethodsNew York, GenomeWeb – As liquid biopsy products make further inroads in the clinic and in clinical research, rather than coalescing around a few dominant technologies or platforms, investigators and entrepreneurs are continuing to explore and advance a wide range of methods for examining genomic and other molecular biomarkers non-invasively.
07.07.2016 | GenomeWeb | AR-V7 and Prostate Cancer
Genomic Health to Market Epic Sciences' AR-V7 Liquid Biopsy TestNew York, GenomeWeb — Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences’ AR-V7 liquid biopsy test in the United States.
07.06.2016 | The Wall Street Journal | AR-V7 and Prostate Cancer
Test aids prostate cancer treatment.New York, Wall Street Journal — Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.
06.14.2016 | DDN News | About Us
Guest Commentary: Back to cancer’s drawing board.By Murali Prahalad of Epic Sciences — A curious problem arises for each new precision oncology therapeutic with a companion diagnostic: Many predicted responders exhibit primary resistance.
06.09.2016 | GenomeWeb | AR-V7 and Prostate Cancer
Epic Sciences' circulating tumor cell prostate cancer test shows promise in new JAMA study.Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR-V7 protein expression test using Epic Sciences’ non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration-resistant prostate cancer.
01.28.2016 | GenomeWeb | Functional Cell Profiling
Epic, Avera ink deal to use liquid biopsy platform in clinical studies.New York, GenomeWeb — Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company’s circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.
01.14.2016 | DDN News | Functional Cell Profiling
Never leave a cell behind.Rocky River, DDNews — Article covering Epic Sciences’ platform technology and describes how it is being used in partnerships with outside research teams.
01.12.2016 | GenomeWeb | AR-V7 and Prostate Cancer
Utility of CTC platform in prostate cancer MDx.New York, GenomeWeb — Epic Sciences was covered in a “Featured In-Depth” story in GenomeWeb Daily News: “Epic Sciences, MSKCC Research Suggests Utility for CTC Platform in Prostate Cancer MDx.”
01.11.2016 | GenomeWeb | About Us
CAP accreditation of Epic Sciences lab.San Diego, GenomeWeb — Epic Sciences has received accreditation from the College of American Pathologists (CAP). The CAP Laboratory Accreditation Program is recognized by the United States government as being equally or more stringent than the federal inspection program and is designed to specifically ensure the highest standard of care for all laboratory samples.
01.05.2016 | Xconomy | About Us
Oncology's future.Xconomy — Article in Xconomy, by Murali Prahalad, Ph.D., president and CEO of Epic Sciences, looks forward, into oncology’s future. The article discusses the intra- and inter- tumor diversity that is often found in cancer patients and what understanding this heterogeneity could mean for treatment.
10.12.2015 | DDN News | About Us
Diagnostics special report.Rocky River, DDNews — Epic Sciences has been featured in a special report on liquid biopsy. This report discussed cancer as a heterogeneous disease and reviews sample choice in research and diagnostics.
08.04.2015 | PharmaVoice | About Us
Epic's CSO, Dena Marinucci, named to PharmaVOICE 100.PharmaVOICE — PharmaVOICE has named Dena Marinucci, Ph.D. CSO of Epic Sciences, to the magazine’s 2015 list of 100 outstanding professionals in the life-sciences industry. Dena was chosen as part of the group of visionary entrepreneurs who recognized an opportunity to fill an industry need and are successfully leading their companies to new heights.
04.22.2015 | GenomeWeb | Functional Cell Profiling
GenomeWeb: Epic Sciences collaborators share data at AACR on single cancer cell analysis, CTC biomarker detection.New York, GenomeWeb — GenomeWeb reported from the annual meeting of the American Association for Cancer Research (AACR), where several research groups presented studies using Epic Science’s no cell left behind™ platform for detecting and analyzing circulating tumor cells (CTCs).
11.19.2014 | Lung Cancer News Today | Lung Cancer
Lung Cancer News Today — Epic Sciences to present CTC-CFDNA method for lung cancer analysis.Innovative cancer diagnostics and treatment development company, Epic Sciences, Inc., will be attending the upcoming 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona to present a poster on a method to comprehensively detect clinically actionable non-small cell lung cancer (NSCLC) biomarkers using circulating tumor cells (CTCs) and circulating free DNA (cfDNA).
05.20.2014 | Cancer Discovery | CTC and Liquid Biopsy
Cancer Discovery: Tracking CTCs may improve cancer treatment.Cancer Discovery — Epic Sciences’ circulating tumor cell (CTC) no cell left behind™ technology was featured in Cancer Discovery’s May 2014 issue. The article discusses how quantifying and characterizing circulating tumor cells (CTC), as a liquid biopsy, is helping doctors to determine the course of therapy and to watch how a patient’s cancer evolves — all with a blood draw.
04.02.2014 | The Scientist | CTC and Liquid Biopsy
The Scientist: Capturing cancer cells on the move.The Scientist — Epic’s circulating tumor cell (CTC) technology was featured in the April 2014 issue of The Scientist. The article discusses how our no cell left behind™ technology can capture all of the CTCs in a blood sample, because Epic’s approach does not rely on cell-enrichment strategies.
02.24.2014 | Discover Magazine | CTC and Liquid Biopsy
Discover Magazine: Personalized cancer treatment, from just a blood sample.Discover Magazine — Blood samples are an invaluable tool, but often they’re just the tip of the diagnostic iceberg, something that determines whether additional, more sensitive tests and scans might be necessary. But new technology being developed by San Diego-based Epic Sciences can determine whether a cancer patient is an appropriate candidate for a drug, and even whether the drug is losing its efficacy.
01.29.2014 | Xconomy | Functional Cell Profiling
Xconomy: Epic Sciences compiling data on ultra-sensitive cancer diagnostic.Xconomy — San Diego’s Epic Sciences said today it has signed an agreement with LabCorp (NYSE: LH) to help speed up European clinical trials that are using Epic’s technology to identify tumor cells in the blood.
02.03.2013 | San Diego Union-Tribune | Functional Cell Profiling
U-T San Diego: Scripps invents way to spot spread of cancer.San Diego, Union Tribune — The Scripps Research Institute has invented an experimental way to spot and analyze cells that break away from solid tumors, possibly giving doctors a faster and better way to treat a variety of cancers.
11.20.2012 | MedCity News | About Us
MedCity News: Cancer diagnostics firm that can enable personalized medicine raises $13M in Series B financing.San Diego, MedCity News — San Diego-based biotech firm Epic Sciences announced Tuesday that the company has raised $13 million to pursue its molecular diagnostics technology that can better detect and monitor cancer as well as enable personalize cancer treatment.
02.17.2012 | Xconomy | CTC and Liquid Biopsy
Xconomist of the week: Peter Kuhn on detecting circulating tumor cells.Xconomy — Worrying whether a solid tissue tumor might spread elsewhere in the body represents one of the biggest unknowns for many cancer patients, according to Peter Kuhn, an associate professor of cell biology at The Scripps Research Institute in San Diego.